Effects of brown rice or white rice on glycemic and lipid metabolism, and vascular function

Effects of brown rice or white rice on glycemic and lipid metabolism, and vascular function - Effects of brown rice or white rice on vascular function

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008370

Enrollment

Registered

2012-07-10

Start date

2012-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

Brown rice group: 1) Brown rice period (2 months) Intake of brown rice as a staple food (2 times / day, 5 days / week). 2) Energy adjustment period (2 months) 3) Follow-up period (2 months)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) HbA1c < 8.0% (JDS) 2) Patients who don't use insulin therapy 3) Patients who don't take alpha-glycosidase inhibitor (alpha-GI) 4) no smoking

Exclusion criteria

Exclusion criteria: 1) Patients with severe vascular, hepatic, renal, cancer, and/or infectious disease 2) Patients who changes drug treatment within 2 months 3) Patients with rapid weight loss 4) Patients who enrolled in another study within 1 month 5) Patients who have eaten brown rice 6) Patients who have taken fiber supplement 7) Pregnancy and breast-feeding patient 8) Patients who have taken warfarin

Design outcomes

Primary

Measure	Time frame
Vascular function (both in fasting and in postprandial state) before and after intervention	—

Secondary

Measure	Time frame
Change in the following data during the intervention period 1) body weight, waist, blood pressure, body fat, abdominal visceral fat 2) IMT (Intima Media Thickness) 3) CAVI (Cardio Ankle Vascular Index) 4) AST, ALT, gamma-GTP, HbA1c, glycoalbumin, Total cholesterol, HDL cholesterol, LDL cholesterol, tPAI-1, hs-CRP, adiponectin, leptin, ADMA, lipid metabolites 5) mRNA expression of M1/M2 phenotype of PBM (TNF-alpha, MCP-1, CD11c, CD163, HO-1) 6) meal tolerance test (0, 30, 60, 90, 120min): glucose, insulin, triglyceride, free fatty acid, glucagon, GLP-1, GIP 7) Urine 8-isoprostane 8) bacterial flora 9) change in the eating behavior and psychosomatic state by questionnaire	—

Measure

Time frame

Change in the following data during the intervention period 1) body weight, waist, blood pressure, body fat, abdominal visceral fat 2) IMT (Intima Media Thickness) 3) CAVI (Cardio Ankle Vascular Index) 4) AST, ALT, gamma-GTP, HbA1c, glycoalbumin, Total cholesterol, HDL cholesterol, LDL cholesterol, tPAI-1, hs-CRP, adiponectin, leptin, ADMA, lipid metabolites 5) mRNA expression of M1/M2 phenotype of PBM (TNF-alpha, MCP-1, CD11c, CD163, HO-1) 6) meal tolerance test (0, 30, 60, 90, 120min): glucose, insulin, triglyceride, free fatty acid, glucagon, GLP-1, GIP 7) Urine 8-isoprostane 8) bacterial flora 9) change in the eating behavior and psychosomatic state by questionnaire

—

Countries

Japan

Contacts

Public ContactKeiko Kondo

Shiga University of Medical Science Department of Public Health

kon@belle.shiga-med.ac.jp077-548-2191

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026